图片: | |
---|---|
名称: | |
描述: | |
性别 | 女 | 年龄 | 36 | 临床诊断 | 乳腺纤维腺瘤 |
---|---|---|---|---|---|
一般病史 | 体检发现左侧乳房肿块,活动可,影像学未见钙化影,提示纤维腺瘤。 | ||||
标本名称 | 乳腺肿块切除标本 | ||||
大体所见 | 灰白灰红色不规则组织一块,2.5cm×2cm×1.5cm,切面大部呈亮白色,质地韧。 |
点评专家:薛德彬(181、182楼 链接:>>点击查看<< )
知之者不如好之者,好之者不如乐之者。(语出幽梦影)
诊断:(左乳)血管源性肿瘤,考虑上皮样血管肉瘤
依据:低倍镜下,乳腺小叶结构存在,小叶外间质见内见异型细胞浸润,弥散分布,裂隙状及条索状,内衬上皮样细胞;高倍镜下,肿瘤细胞似形成大小不等的血管腔样结构,肿瘤细胞大,异型性明显,圆形或多边形,胞浆丰富嗜酸性,核大,核染色质粗糙,未见明显核仁(核仁常常很明显,这应该是上皮样血管内皮的一个特征,包括上皮样血管内皮细胞瘤),局部可见“三个一”,一个管腔,一个内皮细胞,一个红细胞。廖老师曾说过,一个腔内只有一个肿瘤细胞,是血管源性肿瘤的线索,免疫组化:CD31,CD34,第八因子,Fli-1等阳性可支持诊断。
鉴别诊断:1、上皮样血管内皮瘤:瘤细胞异型性不明显,介于良恶性血管肿瘤之间
2、乳腺浸润性小叶癌:瘤细胞黏附性差,列兵样或靶环样排列,ER/PR等阳性
3、乳腺浸润性小管癌:形态温和,管状,肌上皮缺乏,血管源性标记物阴性
4、转移性癌:结合病史及免疫组化结果
(左侧)乳腺组织,乳腺大部分区域呈小叶增生性腺病改变,部分区域乳腺小叶周边可见增生的单个或列兵样排列细胞索在小叶间或围小叶穿插围管状浸润生长;细胞学呈浆细胞样、蝌蚪样、不规则索性、部分呈小管样,胞核大而浓染,核浆比例大,异型性明显。
诊断:(左侧)乳腺恶性肿瘤,浸润性小叶癌可能性大,建议做免疫组化,进一步诊断。
鉴别诊断:1、特殊类型的导管癌或导管小叶来源。2、乳腺间叶肿瘤。
诊断:小管小叶癌,相当于小管癌样小管+线性或条索状小叶癌成分组合而成
低倍见很多小叶结构,小叶未见明确肿瘤样变(可有LCIS和或DCIS,不影响诊断),小叶结构之间可见很多索状和有微小腺腔和或有不易察觉腺腔的小管浸润生长,很像浸润性小叶癌,但小管样结构和小管癌不一样之处在于无明显成角,似乎开窗也太小了。免疫组化介于导管癌和小叶癌之间,主要是表达高分子量CK‘和E-cadherin。预后比小管癌差些,可有淋巴结转移。
原先认为这个是小叶癌的变异型,最近的免疫组化和其它研究证实这个病变仍是导管分化的肿瘤
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA. espositonc@upmc.edu
Tubulolobular carcinoma is a type of mammary carcinoma that displays an admixture of invasive tubules and lobular-like cells. Previous reports have shown it to share clinical similarities to lobular carcinoma, whereas more recent studies have shown it to be E-cadherin positive. The aim of the current study was to further explore the immunophenotype of tubulolobular carcinoma, and to document its natural behavior. Nineteen cases of tubulolobular carcinoma and 10 cases each of tubular and lobular carcinoma were retrieved for comparison analysis. Immunohistochemistry was performed with antibodies against estrogen receptor, progesterone receptor, HER2/neu, 34betaE12, E-cadherin, and the catenins. Twenty-five percent of patients with tubulolobular carcinoma presented with greater than stage I disease, compared to 0 and 60% of patients with tubular and lobular carcinoma, respectively. Two patients with tubulolobular carcinoma had tumor recurrence, one of whom also developed metastasis. The majority of all carcinomas were estrogen and progesterone receptor positive. E-cadherin displayed membranous staining in all tubular and tubulolobular carcinomas, and was negative in all lobular carcinomas. Half of each carcinoma subtype displayed granular cytoplasmic 34betaE12 immunoreactivity. alpha-Catenin exhibited partial or complete membranous staining in all tubulolobular and tubular carcinomas, and was negative in all lobular carcinomas. beta-Catenin displayed membranous staining in tubulolobular and tubular carcinomas, whereas all lobular carcinomas had coarse cytoplasmic immunoreactivity. p120 and gamma-catenin displayed membranous staining in 100% of tubulolobular and tubular carcinomas and cytoplasmic staining in 100% of lobular carcinomas. Tubulolobular carcinoma of the breast is thus a distinct type of mammary carcinoma that displays both tubular and lobular patterns histologically but displays the membranous E-cadherin/catenin complex characteristic of the ductal immunophenotype. Tubulolobular carcinoma appears to be more aggressive than tubular carcinoma, as 16% of patients had lymph node metastases, although all were alive at a mean follow-up of 40 months.
In conclusion, tubulolobular carcinoma of the breast is a distinct type of mammary carcinoma that displays both tubular and lobular patterns histologically but displays the membranous E-cadherin/catenin complex characteristic of the ductal immunophenotype. It may thus be better termed 'ductal carcinoma, tubulolobular subtype', or 'ductal carcinoma with a tubulolobular pattern'. Even in this small group of patients, tubulolobular carcinoma appears to be more aggressive than tubular carcinoma, as 16% of patients had lymph node metastases, although it carries an overall good prognosis, as all patients were alive at a mean follow-up time of 40 months
诊断:(左乳)血管源性肿瘤,考虑上皮样血管肉瘤
依据:低倍镜下,乳腺小叶结构存在,小叶外间质见内见异型细胞浸润,弥散分布,裂隙状及条索状,内衬上皮样细胞;高倍镜下,肿瘤细胞似形成大小不等的血管腔样结构,肿瘤细胞大,异型性明显,圆形或多边形,胞浆丰富嗜酸性,核大,核染色质粗糙,未见明显核仁(核仁常常很明显,这应该是上皮样血管内皮的一个特征,包括上皮样血管内皮细胞瘤),局部可见“三个一”,一个管腔,一个内皮细胞,一个红细胞。廖老师曾说过,一个腔内只有一个肿瘤细胞,是血管源性肿瘤的线索,免疫组化:CD31,CD34,第八因子,Fli-1等阳性可支持诊断。
鉴别诊断:1、上皮样血管内皮瘤:瘤细胞异型性不明显,介于良恶性血管肿瘤之间
2、乳腺浸润性小叶癌:瘤细胞黏附性差,列兵样或靶环样排列,ER/PR等阳性
3、乳腺浸润性小管癌:形态温和,管状,肌上皮缺乏,血管源性标记物阴性
4、转移性癌:结合病史及免疫组化结果
低倍镜非常貌似小叶癌,但切片大部分为增生性腺病,病变处小叶改变也不大,高倍镜细胞立方或多角,似乎有肌上皮(还需组化哟),而非单一的小叶癌样异型细胞,另外纤维增生较温和,不像癌性间质,瘤细胞并不打乱胶原束的排列方向,不破坏间质。确实部分有三个一结构,但乳腺血管肉瘤非常少见,而且血管不丰富,形态不像,只作为鉴别,综上,俺考虑硬化性腺病,但细胞确实有异型,考虑有癌变?组化染肌上皮。
鉴别:小叶癌 化生性癌 血管肉瘤等
组化:CK CK5/6 p63 E-cad CD34 CD31 DES VIM S-100 ER PR SMA p120 ki-67
诊断:乳腺纤维瘤病样梭形细胞癌(CKpan、vimentin阳性,p63,actin 可阳性)。
诊断依据:首先整个病变呈纤维瘤病的结构,某些区域似乎有纤维腺瘤形成,但间质中有很多梭形细胞条索,围绕小叶和导管同心圆状浸润性生长,细胞总体较温和。最后2张图非常重要,在导管内可见坏死,以及和类似于间质内浸润性生长的梭形细胞。故诊断为乳腺纤维瘤病样梭形细胞癌。
鉴别诊断:1、肉瘤(血管肉瘤、血管内皮细胞瘤、梭形细胞脂肪肉瘤),首先本病例血管不够丰富。大体中切面较硬,色灰白,也不符合肉瘤的大体特征。2、其它良性病变(纤维腺瘤病、结节性筋膜炎等)。细胞形态以及浸润性生长+坏死不符合良性病变。上皮标记可鉴别。3、腺肌上皮瘤、以双侧上皮为特点。内衬乳腺上皮。周围肌上皮增生明显。
免疫组化染色:CKpan、vimentin、s-100、E-cadherin、ki-67 CD34 、CD31‘P63’,SMA可鉴别。
诊断:“左侧”乳腺:浸润性乳腺癌, 浸润性导管癌可能性大。
诊断依据:增生性小叶间及乳腺小叶内可见增生的单个、腺管样或条索样排列瘤细胞浸润生长。 瘤细胞异型性明显。并可见导管内癌成分。间质增生。
鉴别诊断:1、浸润性小叶癌,瘤细胞可见散在或“靶形”分布,但瘤细胞可见明显腺管样结构及小片状分布;可行免疫组化进一步鉴别。
2、乳腺恶性间叶肿瘤,肿瘤细胞散在分布,异形明显,部分呈梭形,但瘤细胞明显腺管样、小片样分布,考虑为上皮源性,可行免疫组化进一步鉴别。
免疫组化:P63、Calponin、ER、PR、C-erbB2、Ki-67、desmin、vimentin、EMA、S-100。
zyyzwangjin 离线
hanxiangchun 在线
zhangmy99880 离线